Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Leif William Ellisen, M.D.,Ph.D.

Co-Author

This page shows the publications co-authored by Leif Ellisen and Michael Lawrence.
Connection Strength

0.647
  1. RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer. Clin Cancer Res. 2021 09 01; 27(17):4883-4897.
    View in: PubMed
    Score: 0.236
  2. Aneuploidy and a deregulated DNA damage response suggest haploinsufficiency in breast tissues of BRCA2 mutation carriers. Sci Adv. 2020 01; 6(5):eaay2611.
    View in: PubMed
    Score: 0.214
  3. Identification of Somatically Acquired BRCA1/2 Mutations by cfDNA Analysis in Patients with Metastatic Breast Cancer. Clin Cancer Res. 2020 09 15; 26(18):4852-4862.
    View in: PubMed
    Score: 0.055
  4. Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer. NPJ Precis Oncol. 2019; 3:18.
    View in: PubMed
    Score: 0.052
  5. A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer. Nat Genet. 2017 Oct; 49(10):1476-1486.
    View in: PubMed
    Score: 0.045
  6. Recurrent and functional regulatory mutations in breast cancer. Nature. 2017 07 06; 547(7661):55-60.
    View in: PubMed
    Score: 0.045
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.